INTERPACE BIOSCIENCES, INC.

IDXG | OTC | CIK: 0001054102 | SIC: 3841 Surgical & Medical Instruments & Apparatus | active
Interpace Biosciences, Inc. is a molecular diagnostics company focused on cancer testing, primarily thyroid cancer. Its key products include ThyGeNEXT and ThyraMIR v2, molecular diagnostic tests for thyroid cancer. The company previously offered PancraGEN, a pancreatic cancer test, which lost Medicare reimbursement coverage effective April 24, 2025, leading to its discontinuance. Revenue is derived entirely from clinical diagnostic services.
molecular-diagnosticsthyroid-cancer-testingpancreatic-cancer-testingclinical-laboratory-serviceslaboratory-developed-tests-(ldts)
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/IDXG
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
ThyGeNEXTserviceMolecular diagnostic test for thyroid cancer used in clinical laboratory services.
ThyraMIR v2serviceMolecular diagnostic test for thyroid cancer, a core revenue-generating clinical service.
PancraGENservicePancreatic cancer molecular diagnostic test; discontinued after CMS ceased reimbursement coverage on April 24, 2025.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/IDXG/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub